Original Articles
Vol. 4 No. 3 (2025)
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 2 December 2025
462
Views
113
Downloads
39
HTML
Authors
Background: inherited fibrinogen disorders are characterized by a spectrum of quantitative or qualitative fibrinogen deficiency associated with both a hemorrhagic and thrombotic risk.
Methods: a nationwide survey was conducted in 19 Italian Hemophilia Treatment Centers in order to investigate current diagnostic and management practices for inherited fibrinogen disorders (afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia).
Results: the survey revealed a strong consensus (95% of centers) on the necessity of both functional and antigenic fibrinogen assays for diagnosis, and a preference for fibrinogen concentrate-based treatment (used by >85% of centers). However, significant heterogeneity was observed in critical areas: for hypofibrinogenemia, the definition of a «severe» form varied among centers, and the perceived risk of spontaneous intracranial hemorrhage remained a major point of uncertainty (up to 47% of respondents answered ‘don’t know’ for this risk in hypofibrinogenemia and dysfibrinogenemia). Furthermore, intervention thresholds for major surgical procedures showed a high degree of variability across all three disorders.
Conclusions: the findings highlight areas of consistent practice alongside those requiring further standardization and collaborative research to optimize the care of individuals with these rare bleeding and thrombotic conditions.
Downloads
Download data is not yet available.
Citations
1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39:585-95. DOI: https://doi.org/10.1055/s-0033-1349222
2. Casini A, Neerman-Arbez M, de Moerloose P. Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management. Blood Rev 2021;48:100793. DOI: https://doi.org/10.1016/j.blre.2020.100793
3. Neerman-Arbez M, Casini A. Clinical consequences and molecular bases of low fibrinogenl. Int J Mol Sci 2018;19:192. DOI: https://doi.org/10.3390/ijms19010192
4. Casini A, Moerloose P, Neerman-Arbez M. Clinical, laboratory, and molecular aspects of congenital fibrinogen disorders. Semin Thromb Hemost 2025;51:103-10. DOI: https://doi.org/10.1055/s-0044-1788898
5. Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016;42:356-65. DOI: https://doi.org/10.1055/s-0036-1571340
6. Güven B, Can M. Fibrinogen: Structure, abnormalities and laboratory assays. Adv Clin Chem 2024;120:117-43. DOI: https://doi.org/10.1016/bs.acc.2024.03.004
7. Verhovsek M, Moffat KA, Hayward CPM. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008;83:928-31. DOI: https://doi.org/10.1002/ajh.21293
8. Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999;107:204-6. DOI: https://doi.org/10.1046/j.1365-2141.1999.01681.x
9. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012;10:615-21. DOI: https://doi.org/10.1111/j.1538-7836.2012.04653.x
10. Mohsenian S, Palla R, Menegatti M, et al. Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database. Blood Adv 2024;8:1392-404. DOI: https://doi.org/10.1182/bloodadvances.2023012186
11. Casini A, de Morerloose P. How I treat dysfibrinogenemia. Blood 2021;138:2021-30. DOI: https://doi.org/10.1182/blood.2020010116
12. Casini A, Brungs T, Lavenu-Bombled C, et al. Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. J Thromb Haemost 2017;15:876-88. DOI: https://doi.org/10.1111/jth.13655
13. Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost 2018;16:1887-90. DOI: https://doi.org/10.1111/jth.14216
14. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167:304-26. DOI: https://doi.org/10.1111/bjh.13058
15. Casini A, de Moerloose P, Congenital Fibrinogen Disorders Group. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia 2016;22 898-905. DOI: https://doi.org/10.1111/hae.13061
16. Casini A, Kadir RA, Abdelwahab M, et al. Management of pregnancy and delivery in congenital fibrinogen disorders: communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. J Thromb Haemost 2024;22: 1516-21. DOI: https://doi.org/10.1016/j.jtha.2024.01.008
17. Mohsenian S, Palla R, Menegatti M, et al. Gynecologic and obstetric complications in women with congenital fibrinogen disorders: insights from the Prospective Rare Bleeding Disorders Database. Res Pract Thromb Haemost 2025;9:102960. DOI: https://doi.org/10.1016/j.rpth.2025.102960
How to Cite
1.
Marino R et al. Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers. Bleeding Thromb Vasc Biol [Internet]. 2025 Dec. 2 [cited 2026 Apr. 14];4(3). Available from: https://www.btvb.org/btvb/article/view/372
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Cristina Santoro, Alessandro Casini, Addressing some challenges of congenital fibrinogen disorders in 2023 and beyond , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro, The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Tiziano Martini, Alessandra Valpreda, Marina Marchetti, Alberto Catalano, Laura Contino, Raimondo De Cristofaro, Augusto Bramante Federici, Ilaria Quaglia, Rossana Rossi, Rita Carlotta Santoro, Armando Tripodi, Angelo Claudio Molinari, Diagnostic challenges in current laboratory practice at Italian Hemophilia Centers: findings from a nationwide survey , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. 1 (2026)
- Stefania Cavazza, Gualtiero Palareti*, Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Martina Berteotti, Walter Ageno, Rossella Marcucci, Andrea Stella, Paolo Zamboni, Romeo Martini, The role of dyslipidemia and gender-related risk factors in the management of patients with abdominal aortic aneurysms: a survey from the Italian Society of Angiology and Vascular Medicine and a call to action , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
- Società Italiana di Emostasi e Trombosi, PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO68 | RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER AND MIGRAINE: A COHORT ANALYSIS AMONG DANISH NATIONAL HEALTH SURVEY PARTICIPANTS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- CO38 | Management of pregnancy, delivery, and postpartum in Italian carriers and women with hemophilia A and B , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO07 | Liver transplant in a case of congenital afibrinogenemia , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
1-10 of 16
Next
You may also start an advanced similarity search for this article.
